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Matrix metalloproteinases (MMPs) are group of enzymes thought to play an important role in trophoblastic
and tumor invasion. The aim of our study was to investigate the trophoblastic expression of MMPs and
p53 in normal trophoblast and hydatidiform moles (HM). Paraffin sections of 45 specimens, including 14
complete hydatidiform moles (CM), 15 partial hydatidiform moles (PM), 8 atypical partial hydatidiform
moles (aPM), and 8 controls were selected. Classification of HM was established on histologic criteria and
supported by the DNA ploidy results. Tissue sections from each case were immunostained with mono-
clonal antibodies, cytokeratin-7, MMP-2, MMP-9, tissue inhibitors of metalloproteinases (TIMP)-1, and p53
wild type (p53wt) and mutant types (mutp53). Staining for cytokeratin-7 revealed a positive reaction in
93% of the samples. MMP-2 was mainly expressed in the syncytiotrophoblast of HM and found in 62% of
aPM, 60% PM, and 93% CM. The mutp53 was mainly and focally expressed in syncytiotrophoblastic
cells and was found in 63% of aPM, 80% PM, and 93% CM. Expression of MMP-2 and mutp53 was both
significantly greater in HM vs control group (P , 0.05) and greater in CM vs PM and aPM (P , 0.05).
No significant difference was observed for cytokeratin-7, MMP-9, TIMP-1, and p53wt between the HM sub-
groups and between HM and control group. MMP-2 and mutp53 are overexpressed in HM as compared
with normal trophoblast and might participate in the invasive behavior of the HM.
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Trophoblast invasion, like tumor invasion, is due to an
active secretion of proteolytic enzymes like matrix
metalloproteinases (MMPs) capable of digesting extra-
cellular matrix(1). Gelatinases are a group of the MMPs
implicated in the invasive process by digesting colla-
gen type IV, the major constituent of basement mem-
brane and denatured collagen, the gelatine(2). MMP-9
(92 kDa, gelatinase-B) and MMP-2 (72 kDa, gelatinase-
A) have been shown to mediate invasion of trophoblas-
tic cells in endometrium and proximal myometrium in
normal first trimester pregnancy(2–4). In normal tropho-
blastic tissue, the regulation of trophoblast invasion by
MMPs is believed to be counterregulated by tissue in-
hibitors of metalloproteinases (TIMPs), which are
secreted locally in the extracellular space where they
control the activity of MMPs(5). Among this group of en-
zymes, TIMP-1 is the most widely expressed and acts
by inhibiting the active form of all MMPs(6).
Hydatidiform mole (HM) refers to a pregnancy-
related disease and includes partial hydatidiform
mole (PM) and complete hydatidiform mole (CM)(7–9).
Unlike normal human pregnancy where trophoblast
cells proliferate and differentiate to form the placenta
in a regulated manner, HM placenta are overgrown
and show varying degrees of local invasion and
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metastasis(10). In CM, the villi are cystic and embry-
onic development is usually absent, whereas in PM,
embryonic development is usually observed and
a range of normal and abnormal cystic villi are pres-
ent. CM have a more invasive behavior than PM and
carry a greater risk of developing persistent tropho-
blastic tumor or metastasis(10–13). Following the pre-
vious reports of correlation of MMPs expression with
the invasiveness of tumor cells, it can be presumed
that MMPs expression could be higher in HM than in
normal placental tissue.
The aim of our study was to determine the immuno-
histochemical (IHC) expression of MMP-2, MMP-9,
TIMP-1, and p53 in normal trophoblast compared with
HM and its subgroups. p53 was chosen because this
oncosuppressor is a potent regulator of MMPs(14).
Materials and methods
Patients
Cases with HM (n ¼ 45) were collected from the files
of the Pathology Department, University Hospital of
Lausanne, Switzerland. Histologic evaluation of all ca-
ses was performed on routine sections stained with
hematoxylin and eosin using published criteria by
Szulman and Surti(8). The slides were evaluated by
expert pathologist (R.L.) with special expertise in tro-
phoblastic disease. As controls, six cases were col-
lected from clinically normal pregnancies interrupted
by vacuum for psychosocial or medical reasons that
were unlikely to affect placental structure and func-
tion, and two cases were collected after surgical curet-
tage because of incomplete spontaneous abortion
without hydropic changes.
Histopathology
CM and PM were classified according to histologic cri-
teria and DNA ploidy results. Cases that did not fulfill
the conventional morphologic criteria for either CM or
PM were classified as atypical PM (aPM). This
included specimens where on gross examination there
were no vesicular changes (hydropic villi with diame-
ter of 5 mm or over) as can be seen in both complete
(all vesicular) and partial (focal vesicular) moles
(Fig. 1). Histology of these aPM shows diffuse hy-
dropic villi (up to 2–3 mm in diameter) changes char-
acterized by a focal branching hyperplasia of the
syncytiotrophoblast (ST) without bilaminar (syncytio
and cytotrophoblast) and circumpherential trophoblast
proliferation, as observed in complete and partial
moles. A total of eight such cases were diagnosed as
aPM, 15 as PM, and 14 as CM.
DNA analysis
DNA analysis was performed with the technique
described previously by Hedley et al(15). This was per-
formed in most of the cases on the same paraffin block
that was used for hematoxylin and eosin staining. The
samples mainly presented chorionic villi with limited
contamination from membranes and deciduas. A pla-
centa was classified as tetraploid if the peak in the
G2/M region appeared in more than 25% of the cells
and the DNA index was between 1.90 and 2.1 and
triploid if the DNA index was between 1.4 and 1.60.
Almost all cases (13/14) histologically diagnosed as
CM yielded diploid histograms by flow cytometry,
whereas 6 of the 8 histologically classified as aPM and
11 of 15 diagnosed as PM yielded a triploid histogram
(Table 1).
Immunohistochemistry
IHC studies were performed on formalin-fixed,
paraffin-embedded tissue section using the avidin–
biotin–peroxidase complex method(16). Sections were
cut (5 lm) thick, deparaffinized in xylene, and dehy-
drated in a descending ethanol series (from 100%
to 70%). The antibody for cytokeratin-7 was mouse
monoclonal antibody anti-human cytokeratin-7 (Dako,
Glostrup, Denmark; diluted 1:500). The antibodies for
MMP-2 and MMP-9 were mouse monoclonal anti-
bodies (both from Oncogene Research, Steheten AG,
Basel, Switzerland) and used at a 1:400 dilution. The
antibody to TIMP-1 was a polyclonal (Ab-1) from
Anawa (Wanger, Switzerland) and was used at a dilu-
tion of 1:100. Antibody for p53 mutated (mutp53) (Ab-
3) and P53 wild type (p53wt) (Ab-5) were both from
Figure 1. Atypical molar pregnancy with chorionic villi presenting
a prominent ST showing a branching pattern. H&E 2603.
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Oncogene Research and used at a 1:10 dilution. A sec-
tion of breast cancer with a known negative immuno-
reactivity for p53wt and positive for mutp53 was
included as a positive control.
Quantitative evaluation of cytokeratin-7, MMP-2,
MMP-9, TIMP-1, p53wt, and mutp53
Immunoreactivity of the tissue was graded semiquan-
titatively according to the intensity of staining as nega-
tive (2), weakly positive (,50% positive ¼ 1), and
strongly positive (.50% positive ¼ 11). Cellular lo-
calizations and the frequency of positive reactions for
each antigen were recorded. For all cases, the presence
or absence of nuclear staining was assessed in the
three following cell types: cytotrophoblast, ST, and ex-
travillous trophoblast (EVT). All the evaluation was
performed by the expert pathologist blinded to the
original diagnosis, the hematoxylin and eosin histo-
logic appearance, and to the results of cytometry.
Hofbauer cells were not considered because their posi-
tivity can be the result of macrophagic activity.
Statistical analysis
Statistical analysis was performed using the Stata Sta-
tistic software package (release 5.0; Stata Corporation,
College Station, TX). The correlation between categori-
cal variables was assayed by using the two-tailed
Fisher exact test. All P values resulted from the use of
two-sided statistical tests and P values , 0.05 indi-
cated statistically significant differences.
Results
Patient’s characteristics
The median ages for the patients at diagnosis and ges-
tational age for the different histology are given in
Table 1. All original diagnoses were based on mor-
phology and DNA ploidy analysis (Table 2), as re-
ported in the Materials and methods section.
Immunohistrochemistry
Staining for cytokeratin-7 revealed a positive reaction
(cytotrophoblast) in 42 out of 45 samples, cytokeratin-
positive samples were cases as well as controls, and
no significant differences could be seen between the
groups (Fig. 2).
p53wt did not show any immunoreactivity in nor-
mal trophoblast (Table 3). In the HM group, only few
cases (3/37) showed a weak expression in cytotropho-
blastic cells.
Positive albeit focally expression of mutp53 was
observed in most (81%) of the HM cases. However, in
the control group no expression was found, except in
one case (Table 3). Positive cells were found to be
restricted to the villous trophoblast, essentially in the
ST, whereas EVT showed an absence of immunostain-
ing. There was a statistical significance in mutp53 ex-
pression between normal placenta and HM (P , 0.05,
Fisher exact test).
The percentage of positive expression of mutp53
varied in different groups of HM. In CM immunoreac-
tive nuclei were found in 93% of cases. The expression
of mutp53 was significantly higher in CM with obvi-
ous hyperplasia of trophoblast.
In the other groups, mutp53 was positive in 63% of
aPM and 80% of PM (Table 3) (Fig. 3). There was a sta-
tistical significance in mutp53 expression between nor-
mal placenta and HM (P , 0.05, Fisher exact test).
MMP-2 was essentially expressed in the ST (except
in the control group) and EVT in normal trophoblast
and HM (Table 4) (Fig. 4). The ST in PM and CM had
significantly increased positivity for MMP-2 as com-
pared with the control group (P , 0.05) (Table 4).
Table 1. Clinical characteristics of patients with normal trophoblast, aPM, PM and CM
Control group (n ¼ 8) aPM (n ¼ 8) PM (n ¼ 15) CM (n ¼ 14)
Agea 25 (15–31)* 26 (21–38)* 31 (22–43)* 28 (14–44)*
GA 10 (9–21)* 12 (10–14)* 12 (7–21)* 11 (8–13)*
GA, gestational age (GA unknown for two CM cases).
*Results are shown as median (range).
aMaternal age at diagnosis.
Table 2. Flow cytometry analysis of DNA ploidy in normal
trophoblast, aPM, PM, and CM
Sample Total Diploid Triploid Tetraploid
N N (%) n (%) n (%)
Control group 8 8 (100) — —
aPM 8 — 6 (75) 2 (25)
PM 15 — 11 (73) 4 (27)
CM 14 13 (93) — 1 (7)
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MMP-9 expression was observed in all the groups
(control group, aPM, PM, and CM), in the cytotropho-
blast, and rarely in the EVT (Table 4). No significant
difference was observed in MMP-9 expression
between normal placenta and HM.
TIMP-1 expression was weak in almost all speci-
mens. We observed only a few positive cases in the ST
of aPM, PM, and CM. The slightly increased expres-
sion of TIMP-1 was observed in the HM group as com-
pared with normal pregnancy and did not reach
statistical significance.
Discussion
The role of MMPs and their inhibitors in the invasive
properties of trophoblastic cells has been studied in
normal human placenta(17). In cancer, MMPs have also
been studied, and it seems that tumors cells utilize the
matrix-degrading capability of these enzymes to spread
to distant sites and to promote the growth of the cells
once they have metastatized(18). To date, limited re-
search has been carried out on the role of MMPs in HM.
Because HM are characterized by an abnormal
growth of chorionic tissues with varying degrees of
local invasion and metastases, it can be assumed that
MMPs could be differently expressed in this type of
abnormal conception. In the present study, we tested
this hypothesis by IHC analysis of MMP-2, MMP-9,
TIMP-1, p53wt, and mutp53 in normal placenta, aPM,
PM, and CM.
MMP-2 expression was reported to be higher in HM
than in first trimester placenta(19,20). This is consistent
with the results of the present study, where stronger
staining was observed in the villous trophoblast of
aPM, PM, and CM as compared with normal placenta.
Moreover, we observed a significant increased expres-
sion of MMP-2 in the HM subgroups compared with
the control group, with CM having an enhanced posi-
tivity as compared with aPM and PM. The fact that
MMP-2 expression was observed mainly in ST and in
EVT suggests that this protein can be an indicator of
proliferative and invasive activity. This overexpression
could contribute to the higher risk of neoplastic
behavior generally observed in HM.
In our study, expression of MMP-9 was similar in all
four subgroups. This is consistent with the IHC study
of Vegh et al.(19) and the quantitative studies using
specific enzyme-linked immunosorbent assays per-
formed by Okamoto et al.(20) where no significant dif-
ference in MMP-9 levels were observed between first
trimester placenta and HM.
Expression of TIMP-1 was found in ST in all four
subgroups, but in general, staining was weak. There
was no significant difference between normal placenta
and HM. Okamoto et al.(20) observed also that TIMP-1
expression was similar between normal and molar
pregnancy. In contrast, these investigators observed
that TIMP-2 was significantly reduced at both mRNA
and protein levels in the HM tissue (5.8-fold decrease),
and they suggested that the imbalance of MMP-2/
TIMP-2 in favor of MMP-2 activity may be a critical
factor for trophoblast invasion(20).
The tumor-suppressor gene p53 is known to play
a central role in the protection against the propagation
of DNA damage, primarily by inducing cell cycle
Figure 2. Strongly positive cytokeratin-7 immunoreactivity in vil-
lous cytotrophoblast (arrows) from molar pregnancy. 1003.
Table 3. Mutant p53expression in normal trophoblast, CM, PM, and aPM
Control group (n ¼ 8) aPM (n ¼ 8) PM (n ¼ 15) CM (n ¼ 14)
2 (%) 1 (%) 11 (%) 2 (%) 1 (%) 11 (%) 2 (%) 1 (%) 11 (%) 2 (%) 1 (%) 11 (%)
p53 mutant type ST 7 (88) 1 (12) — 3 (37) 5 (63) — 3 (20) 12 (80) — 1 (7) 10 (72) 3 (21)
CT 8 (100) — — 6 (75) 2 (25) — 15 (100) — — 14 (100) — —
EVT 8 (100) — — 8 (100) — — 15 (100) — — 14 (100) — —
p53 wild type ST 8 (100) — — 8 (100) — — 15 (100) — — 14 (100) — —
CT 8 (100) — — 8 (100) — — 14 (93) 1 (7) — 12 (79) 2 (21) —
EVT 8 (100) — — 8 (100) — — 15 (100) — — 14 (100) — —
CT, cytotrophoblast; EVT, extravillous trophoblast; ST, syncytiotrophoblast.
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arrest or apoptosis. Mutation of p53, which is the most
frequent genetic alteration detected in human cancer,
inactivates this growth regulatory function and causes
a loss of tumor-suppressive activity(21). In most of the
studies, p53 expression is increased in HM, but this
overexpression is presumed to be due to an upregula-
tion of p53wt rather than the mutp53 gene(21–31). In
our study, using conventional IHC for detecting
p53wt, we have found no immunoreactivity in normal
pregnancy and scattered immunoreactivity in ST cells
in HMs. As reported previously, p53wt may be diffi-
cult to demonstrate in trophoblastic tissue. Reasons
may be the short half-life of the p53wt protein, the
conformational state of the p53 protein, which is not
recognized by the antibody p53wt, or the p53 binds to
cytoplasmic or nuclear proteins and the epitodes are
not recognized by the conformation-specific mono-
clonal antibodies(32). It is generally considered that the
increased expression observed of p53 in normal pla-
centa is not due to a mutation of the gene as in malig-
nant tumors but rather to a physiologic upregulation
that could be a mechanism for controlling trophoblast
proliferation and invasion in normal placenta(33). Our
results indicate that expression of mutp53 is signifi-
cantly increased in HM as compared with control
group, but these findings do not necessarily mean that
the mutp53 has lost its suppressive activity. It has
been suggested previously that different mutations do
not essentially lead to a completely identical pheno-
type and that only some specific mutations may
contribute to a more aggressive behavior(34). Webley
et al.(34) proposed that the various mutp53 should be
classified according to their conformation as recog-
nized by antibodies. Thus, our results suggest that the
mutp53 are increased in HM as compared with nor-
mal placenta, but it could be a different conformation
of tertiary folding of the polypeptide or binding to
proteins rather than a true gene mutation. It is possi-
ble that the different phenotype observed in HM may
confer different biologic activity.
Figure 3. Distinctly positive MMP-2 immunoreactivity in pro-
liferating syncytium trophoblast (arrows) from molar pregnancy.
1003.
Table 4. Immunostaining of normal trophoblasts, CM, PM, and aPM
Control group (n ¼ 8) aPM (n ¼ 8) PM (n ¼ 15) CM (n ¼ 14)
2 (%) 1 (%) 11 (%) 2 (%) 1 (%) 11 (%) 2 (%) 1 (%) 11 (%) 2 (%) 1 (%) 11 (%)
MMP-2 ST 8 (100) — — 3 (38) 4 (50) 1 (12) 6 (40) 9 (60) — 1 (7) 7 (50) 6 (43)
CT 8 (100) — — 8 (100) — — 15 (100) — — 14 (100) — —
EVT 2 (25) 6 (75) — 6 (25) 2 (25) — 11 (73) 3 (20) 1 (7) 13 (93) 1 (7) —
MMP-9 ST 8 (100) — — 8 (100) — — 15 (100) — — 14 (100) — —
CT — 8(100) — — 1 (12) 7 (87) 3 (20) 8 (53) 4 (27) — 13 (93) 1 (7)
EVT 8 (100) — — 8 (100) — — 13 (87) — 2 (13) 14 (100) — —
TIMP-1 ST 8 (100) — — 7 (88) 1 (12) — 13 (77) 2 (13) — 11 (88) 3 (22) —
CT 8 (100) — — 8 (100) — — 15 (100) — — 14 (100) — —
EVT 8 (100) — — 8 (100) — — 15 (100) — — 14 (100) — —
CT, cytotrophoblast; EVT, extravillous trophoblast; ST, syncytiotrophoblast.
Figure 4. Focally positive p53 mutant immunoreactivity in ST (ar-
rows) from molar pregnancy. 1003.
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Collectively, the present study demonstrates that
MMP-2 and mutp53 are increased in HM as compared
with normal placenta indicating that they may play
a role in uncontrolled trophoblastic proliferation
observed in HM. Finally, the various published reports
are contradictory regarding mutp53; this may be
partly explained by the different technologies used,
the different clinical characteristics of patients, and the
potential pitfalls in IHC. Further larger studies are
probably needed to determine the role of mutp53 type
in the pathogenesis of HM disease.
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